Is obsessive–compulsive disorder an autoimmune disease?

Paul D. Arnold, Margaret A. Richter

Abstract

OBSESSIVE–COMPULSIVE DISORDER (OCD) IS A COMMON and debilitating neuropsychiatric disorder. Although it is widely believed to have a genetic basis, no specific genetic factors have been conclusively identified as yet, leading researchers to look for environmental risk factors that may interact with an underlying genetic susceptibility in affected individuals. Recently, there has been increasing interest in a possible link between streptococcal infections and the development of OCD and tic disorders in children. It has been suggested that OCD in some susceptible individuals may be caused by an autoimmune response to streptococcal infections, that is, a similar biological mechanism to that associated with Sydenham’s chorea. The term “pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections” (PANDAS) has been used to describe a subset of children with abrupt onset or exacerbations of OCD or tics, or both, following streptococcal infections. Affected children have relatively early symptom onset, characteristic comorbid symptoms and subtle neurological dysfunction. Neuroimaging studies reveal increased basal ganglia volumes, and the proposed cause involves the cross-reaction of streptococcal antibodies with basal ganglia tissue. Vulnerability to developing PANDAS probably involves genetic factors, and elevated levels of D8/17 antibodies may represent a marker of susceptibility to PANDAS. Prophylactic antibiotic treatments have thus far not been shown to be helpful in preventing symptom exacerbations. Intravenous immunoglobulin therapy may be an effective treatment in selected individuals. Further understanding of the role of streptococcal infections in childhood-onset OCD will be important in determining alternative and effective strategies for treatment, early identification and prevention of this common and debilitating psychiatric disorder.

Sydenham’s chorea: a medical model for OCD

Sydenham’s chorea, which is a neuropsychiatric syndrome that usually occurs in prepubertal children, may represent a “medical model” of onset of OCD in childhood. Sydenham’s chorea develops following group A β-hemolytic streptococcal infections and is one manifestation of rheumatic fever according to the Jones criteria. In a process known as “molecular mimicry,” antistreptococcal antibodies
cross-react with basal ganglia proteins, triggering an inflammatory response and producing the symptoms of Sydenham’s chorea.

In addition to the chorea that gives the syndrome its name, there are characteristic psychiatric symptoms, including a syndrome similar to attention-deficit hyperactivity disorder and emotional lability. Obsessive–compulsive symptoms, which were first described in patients with Sydenham’s chorea by Osler, have been well documented in prospective studies of the syndrome, leading to the suggestion that OCD may represent a “forme fruste,” or an atypical, incomplete form, of Sydenham’s chorea.

**PANDAS: a proposed OCD subtype**

Longitudinal studies of children with OCD identified a subgroup with a course of illness characterized by the dramatic onset of symptoms or their exacerbation, or both, one-third of whom exhibited “choreiform” movements resembling the chorea of Sydenham’s chorea. The exacerbations of symptoms in some of these children were correlated with a history of recent streptococcal infections. Studies of children presenting with tics also raised the possibility that some children with neuropsychiatric disorders have symptoms caused or exacerbated by streptococcal infections.

Following up on these early clinical observations, a group based at the US National Institute of Mental Health recruited children with presumed streptococcal-induced OCD based on a set of diagnostic criteria that they had developed. The term “pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections” (PANDAS) was coined to describe a putative subtype of children with OCD and tic disorders who met all 5 working criteria. Table 1 summarizes these criteria and other diagnostic guidelines gleaned from the current literature.

The prevalence of PANDAS is unknown. There is one report on the prevalence of streptococcal-induced exacerbations in a group of children presenting with tics, 11% of whom had a history of exacerbations within 6 weeks of a streptococcal infection. Limitations of this study include its setting in a highly specialized clinic, which limits its generalizability to other populations with tic disorders, and its reliance on retrospective historical data instead of objective laboratory findings such as antistreptococcal antibodies. Two studies have evaluated antistreptococcal antibodies in

<table>
<thead>
<tr>
<th>Table 1: Criteria for the diagnosis of PANDAS* and guidelines for the clinician</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Diagnostic criteria for PANDAS†</strong></td>
</tr>
<tr>
<td>Presence of OCD or a tic disorder, or both</td>
</tr>
<tr>
<td>Pediatric onset, with symptoms beginning between the age of 3 yr and puberty</td>
</tr>
<tr>
<td>Episodic course characterized by the abrupt onset of symptoms or by dramatic symptom exacerbations</td>
</tr>
<tr>
<td>Temporal association between symptom exacerbations and GABHS infection</td>
</tr>
<tr>
<td>Association with neurological abnormalities during symptom exacerbations</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

Note: PANDAS = pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, OCD = obsessive–compulsive disorder, ADHD = attention-deficit hyperactivity disorder, GABHS = Group A β-hemolytic streptococcal, ASO = antistreptolysin O, antiDNAse B = antideoxyribonuclease-B.

*Adapted from Swedo et al.†

†All 5 criteria are required for the diagnosis of PANDAS.
significant correlation with compulsive behaviour. Antistreptococcal antibody levels were found to correlate with severity of symptoms in one report. The PANDAS syndrome is believed to result from antistreptococcal antibodies that have cross-reacted with basal ganglia tissue, as has been demonstrated in Sydenham’s chorea. Consistent with this model, the following findings have been reported: significantly elevated antineuronal antibodies in children with PANDAS and related neuropsychiatric disorders, increased basal ganglia volumes on volumetric MRI in subjects with PANDAS and higher antistreptococcal antibodies that correlated with increased basal ganglia volumes in subjects with either attention-deficit hyperactivity disorder or OCD. Taken together, these findings are consistent with autoimmune-mediated inflammation of the basal ganglia, although further research is required to confirm this association, and many unanswered questions remain. For example, it is not clear whether this autoimmune mechanism is specific to OCD and tic disorders or has implications for other childhood neuropsychiatric disorders. This was highlighted by a recent study reporting a significant correlation of antistreptococcal antibody titres with a diagnosis of attention-deficit hyperactivity disorder, but not with OCD or tic disorders.

Predisposing factors for PANDAS

Streptococcal infections are ubiquitous in childhood, however, neuropsychiatric disorders are not, suggesting that only certain individuals are predisposed to develop the PANDAS phenotype. Vulnerable individuals may have a genetic predisposition to developing neurotransmitter dysfunction or to formation of antistreptococcal antibodies that cross-react with neuronal proteins, or may have a form of immune dysregulation, or both.

D8/17, which is a monoclonal antibody that identifies a specific B lymphocyte cell-surface marker, is one possible susceptibility factor for PANDAS. Significantly elevated levels of this marker have been found in individuals with rheumatic fever and to a lesser extent in their family members when compared with controls. It is, thus, considered a possible trait marker, indicating genetic susceptibility to rheumatic fever (and by inference, to Sydenham’s chorea). To date, elevated levels of antibodies that recognize the D8/17 marker have been demonstrated in children with PANDAS, and more generally in subjects with early onset OCD and tic disorders. In a sample of children with autism, D8/17 expression was shown to be significantly correlated with compulsive behaviour. Although the D8/17 data are suggestive, the functional significance of this marker is unknown, and further investigation is needed to clarify its etiological and clinical significance.

Elevated rates of tic disorders and OCD have been reported in first-degree relatives of children with PANDAS, which is comparable to previous observations in relatives of individuals with OCD and tic disorders, indicating that genetic factors may be important in conferring vulnerability to the PANDAS subtype. However, although a number of candidate genes have been implicated in OCD, there are no published reports of molecular genetics studies of individuals with PANDAS.

A few studies have measured cytokines or immune cells in subjects with OCD. In addition to acting as protein messengers between immune cells, cytokines are also known to influence central nervous system signalling and, therefore, may play a role in the pathophysiology of a number of psychiatric and neurological disorders. A relative skewing toward type 1 cytokine production in cerebrospinal fluid has been demonstrated in pediatric patients with OCD. Various immunological abnormalities reported in adult subjects with OCD have not been consistently replicated, and other studies have produced negative findings.

In summary, although it is presumed that individuals who develop PANDAS in the presence of streptococcal infections are vulnerable as a result of a genetic predisposition or a form of immune dysregulation, or both, this has yet to be clearly demonstrated. Interesting preliminary findings in PANDAS that require further investigation include the presence of elevated levels of D8/17 antibodies, elevated rates of tic disorders and OCD in first-degree relatives, and immunological abnormalities reported in individuals with OCD.

Approach to the diagnosis of PANDAS

We recommend evaluation of all children who present with the sudden onset or exacerbation of obsessive–compulsive symptoms, using the approach summarized in Fig. 1. This diagnostic algorithm, which is based on the literature summarized earlier as well as our clinical judgement, begins with a history-taking, mental status examination and focused physical examination. Initial investigations in children with a history suggestive of streptococcal infection or a strong family history of rheumatic fever, or both, should include throat cultures and antistreptolysin O titres. These titres should be repeated after an interval of approximately 3–4 weeks, because a correlation of symptom sever-
ity with changes in antibody levels is far more informative than an isolated antistreptolysin O titre. We recommend antistreptolysin O titre, because the other antistreptococcal test reported in the PANDAS literature, namely, anti-deoxyribonuclease-B (antiDNAse B), is expensive and not widely available in Canada. The D8/17 marker is an experimental assay that is not available for routine clinical use.

**Treatment of PANDAS**

Current first-line treatments for OCD include pharmacological treatment with serotonin reuptake inhibitors (SRIs) and cognitive behavioural therapy. Researchers have reported response rates of between 50% and 75% for pharmacotherapy and from 67% to 100% for cognitive behavioural therapy. With the accumulating evidence that PANDAS represents a distinct autoimmune subtype, it is now possible to examine various therapies for the disorder targeting either the infectious trigger for the illness or the immune response itself. Recently, 2 randomized controlled trials have evaluated these approaches to the treatment of children with PANDAS. In the first study, patients received either 4 months of penicillin V administered orally followed by 4 months of placebo, or placebo followed by

---

**Fig. 1: Assessment and treatment of children presenting with abrupt-onset obsessive–compulsive disorder (OCD) or tic disorders. ADHD = attention-deficit hyperactivity disorder, ASO = antistreptolysin O, CBT = cognitive behavioural therapy, SRIs = serotonin reuptake inhibitors, NIMH = US National Institute of Mental Health, PANDAS = pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections.**
Evidence regarding the origin and pathogenesis of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS)

- Elevated antineuronal antibodies
- Increased basal ganglia volume measured using volumetric MRI
- Elevated levels of cells expressing the D8/17 marker
- Positive family history of obsessive–compulsive disorder and tic disorders
- Evidence of response to immunomodulatory therapies

Penicillin V. There was no difference between the active and placebo phases in the severity of obsessive–compulsive symptoms or tics. However, the penicillin regimen used was ineffective in preventing infections and, consequently, no conclusions could be drawn regarding the efficacy of penicillin prophylaxis in preventing exacerbations of tics or OCD symptoms.

In the second study, children with severe PANDAS received one of three treatments: plasma exchange, intravenous immunoglobulin, or placebo (sham intravenous immunoglobulin). When subjects were assessed one and 12 months post treatment and compared with the placebo group, both plasma exchange and intravenous immunoglobulin were associated with striking improvements in obsessive–compulsive symptoms, anxiety and overall functioning. An open trial of plasma exchange in a small group of children with treatment-refractory OCD without a history of streptococcal infections failed to show any therapeutic benefit. These findings demonstrate that immunomodulatory treatments may represent an efficacious treatment for PANDAS specifically and are probably ineffective in treating other forms of OCD. Plasma exchange and intravenous immunoglobulin are highly invasive, require admission to hospital and have not been directly compared with more traditional therapies such as serotonergic medications and cognitive behavioural therapy. However, as a result of recent publicity surrounding PANDAS, parents and physicians in the United States have been seeking immunomodulatory treatments for children with OCD and tic disorders despite the potential risks. This has led the US National Institute of Mental Health to issue a warning to parents and clinicians that plasma exchange and intravenous immunoglobulin are not to be used outside research protocols.

Our recommended approach to treatment, based on the literature summarized above as well as our clinical judgement, is summarized in Fig. 1. Standard therapies shown to be efficacious in the treatment of OCD and tic disorders should still be used as first-line treatment, accompanied by careful monitoring and early treatment of group A β-hemolytic streptococcal infections. However, in treatment-refractory children with a clear PANDAS course, prophylactic antibiotics might be considered in consultation with a pediatrician.

Competing interests: None declared.

Contributors: Dr. Arnold cowrote the initial outline of the article, performed the literature review, prepared the initial draft of the article, designed the figure and table, and cowrote the final version. Dr. Richter cowrote the initial outline of the article, contributed additional references to the literature review, performed revisions to the initial draft and cowrote the final version.

References


Correspondence to: Dr. Margaret A. Richter, Centre for Addiction and Mental Health, 250 College St., Toronto ON M5T 1R8; fax 416 979-6853; peggy_richter@canhnet.net

CMA Leadership Workshop for Medical Women 2001
November 23–24, 2001
Royal York
Toronto, Ontario

This is the 7th annual workshop for women physicians and women in academic medicine who are interested in leadership roles in medicine.

Learn from leaders in the fields of medicine, business and politics.

Registration is limited. For information, or to be placed on the preferred mailing list, contact:
CMA Professional Programs
800 663-7336 or 613 731-8610 x2261
Professional_Development